Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$13.85
-0.47 (-3.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-22.0M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.6B
P/E
47.8x
↑EV/EBITDA
14.7x
↑ROE
3.9%
↑Gross Margin
26.2%
↓Debt/Equity
0.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.6%
FCF CAGR
—
FCF margin
-0.8%
FCF / Net income
-0.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $844.5M · net income $62.2M · FCF $-6.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $844.5M | $844.5M | $827.4M | $727.4M | $738.0M |
| Net Income | $62.2M | $62.2M | $29.4M | $-54.1M | $31.5M |
| EBITDA | $158.4M | $158.4M | $126.1M | $28.8M | $109.3M |
| EPS | 0.35 | 0.35 | 0.17 | -0.32 | 0.18 |
| Gross Margin | 26.2% | 26.2% | 21.3% | 16.0% | 17.7% |
| Operating Margin | 10.0% | 10.0% | 6.3% | -0.4% | 3.0% |
| Net Margin | 7.4% | 7.4% | 3.6% | -7.4% | 4.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.20 | 0.20 | 0.21 | 0.19 | 0.03 |
| Current Ratio | 4.69 | 4.69 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.8M | $-6.8M | $-22.0M | $-181.5M | $-22.5M |
| Returns | |||||
| ROE | 3.9% | 3.9% | 2.3% | -4.3% | 2.4% |
| Valuation | |||||
| P/E | 47.76 | 47.76 | 75.71 | — | 71.39 |
| EV/EBITDA | 14.68 | 14.68 | 17.25 | 81.45 | 17.93 |
| P/B | 1.55 | 1.55 | 1.77 | 1.94 | 1.69 |
| Growth & Yield | |||||
| Revenue Growth | 2.1% | 2.1% | 13.7% | -1.4% | — |
| EPS Growth | 105.9% | 105.9% | 153.1% | -277.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
52.0%
EPS terminal req.
$1.23
Spread vs growth
53.9%
5Y implied EPS CAGR
33.6%
EPS terminal req.
$1.49
Spread vs growth
72.3%
10Y implied EPS CAGR
21.2%
EPS terminal req.
$2.39
Spread vs growth
84.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.2%
Start / end P/E
98.4x → 39.6x
EPS bridge
0.17 → 0.35
Residual
-63.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.